BioAtla, Inc.
BCAB
$1.23
-$0.03-2.38%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -22.73% | -81.82% | -81.82% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.73% | -81.82% | -81.82% | -100.00% | -- |
| Cost of Revenue | -53.67% | -37.45% | -30.94% | -36.28% | -37.20% |
| Gross Profit | 61.57% | 26.75% | 20.20% | 25.18% | 49.97% |
| SG&A Expenses | -27.18% | -20.48% | -18.84% | -17.52% | -13.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.34% | -32.78% | -27.83% | -31.82% | -32.01% |
| Operating Income | 50.41% | 24.74% | 19.80% | 23.12% | 42.01% |
| Income Before Tax | 47.15% | 18.20% | 14.57% | 20.91% | 43.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.15% | 18.20% | 14.57% | 20.91% | 43.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.15% | 18.20% | 14.57% | 20.91% | 43.08% |
| EBIT | 50.41% | 24.74% | 19.80% | 23.12% | 42.01% |
| EBITDA | 50.13% | 24.22% | 19.29% | 22.85% | 42.12% |
| EPS Basic | 53.60% | 31.38% | 29.44% | 32.28% | 49.41% |
| Normalized Basic EPS | 54.20% | 31.93% | 29.44% | 32.28% | 49.41% |
| EPS Diluted | 53.60% | 31.38% | 29.44% | 32.28% | 49.41% |
| Normalized Diluted EPS | 54.20% | 31.93% | 29.44% | 32.28% | 49.41% |
| Average Basic Shares Outstanding | 28.83% | 23.32% | 21.11% | 16.89% | 11.77% |
| Average Diluted Shares Outstanding | 28.85% | 23.32% | 21.11% | 16.89% | 11.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |